Prostate Cancer Agents: Jevtana (cabazitaxel) — Continuation of Therapy
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization for Jevtana (cabazitaxel) administered under the medical benefit for MassHealth members with metastatic castration-resistant prostate cancer. It establishes documentation requirements for members new to the plan, clinical criteria for authorization, and approval duration.
The policy added a requirement that Jevtana be used with a gonadotropin-releasing hormone analog or that the member have undergone bilateral orchiectomy.
The policy was reformatted and its references were updated.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.